Physician profile
John D Goosey
NPI 1215922406
$29,149.41
in general payments reported to CMS, 2019-2025
27 companies · $791 in 2025
The $791 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $4,611 · 2021: $3,928 · 2022: $16K · 2023: $1,052 · 2024: $899 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $17,088.20 | 2020-2022 | |
| Dompe US, INC. | $4,379.24 | 2019-2024 | Oxervate |
| Alcon Vision LLC | $1,673.36 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Abbvie INC. | $930.54 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $639.69 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $616.55 | 2022-2025 | Vyzulta, Ic-8 Apthera Iol, Lotemax Sm |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $593.76 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $580.52 | 2019-2024 | Cequa |
| Allergan, INC. | $513.09 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $411.73 | 2019-2025 | Catalys System, Tecnis Simplicity, Veritas Vision System |
| Oyster Point Pharma, INC. | $362.71 | 2022-2024 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $339.57 | 2019-2022 | |
| Shire North American Group INC | $169.80 | 2019 | |
| Kala Pharmaceuticals, INC. | $148.99 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $139.77 | 2024-2025 | Xdemvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $118.64 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $106.73 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $89.70 | 2019-2021 | |
| Rxsight INC | $69.57 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $64.12 | 2019 | |
| Biotissue Holdings INC. | $46.48 | 2024-2025 | |
| Sight Sciences, INC. | $23.08 | 2020 | |
| Eyepoint US, INC. | $22.58 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.99 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goosey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.